Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency : a cross-sectional survey of physicians from the global phase 3 study
Copyright © 2023 Gomez, Lamoureux, Turner-Bowker, Loftus, Maghnie, Miller, Polak and Yaworsky..
Introduction: The standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing. We describe physicians' preference for, experiences, and satisfaction with once-weekly somatrogon vs once-daily rhGH.
Methods: English-speaking investigators from somatrogon's global phase III study (NCT02968004) with prior experience using once-daily rhGH were included. Participants answered an online survey containing 14 closed- and open-ended items.
Results: Twenty-four pediatric endocrinologists (41.7% men; 79.2% practiced at public/private hospitals) from 12 countries with 25.8 ± 12.0 years' experience treating pGHD completed the survey. In terms of the time and effort required to explain device instructions, injection regimen, procedure for missed injection, and address patients'/caregivers' concerns, a similar proportion of physicians chose once-weekly somatrogon and once-daily rhGH; 62.5% physicians indicated that once-daily rhGH required greater effort to monitor adherence. Overall, 75% preferred once-weekly somatrogon over once-daily rhGH, 79.2% considered once-weekly somatrogon to be more convenient and less burdensome, and 83.3% were likely to prescribe somatrogon in the future. Overall, 50% felt that once-weekly somatrogon was more beneficial to patients, while 50% chose "No difference". Most physicians (62.5%) felt both regimens were equally likely to support positive long-term growth outcomes and reduce healthcare utilization. More physicians were "very satisfied" with once-weekly somatrogon (62.5%) than with once-daily rhGH (16.7%). Reduced injection frequency, patient and caregiver burden, increased convenience, and improved adherence were reasons for these choices.
Conclusion: Physicians had a positive experience with, and perception of, treating pGHD with once-weekly somatrogon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 14(2023) vom: 01., Seite 1254424 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gomez, Roy [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.11.2023 Date Revised 16.11.2023 published: Electronic-eCollection ClinicalTrials.gov: NCT02968004 Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2023.1254424 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364466626 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364466626 | ||
| 003 | DE-627 | ||
| 005 | 20231226095506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2023.1254424 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364466626 | ||
| 035 | |a (NLM)37955005 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gomez, Roy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency |b a cross-sectional survey of physicians from the global phase 3 study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.11.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT02968004 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Gomez, Lamoureux, Turner-Bowker, Loftus, Maghnie, Miller, Polak and Yaworsky. | ||
| 520 | |a Introduction: The standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing. We describe physicians' preference for, experiences, and satisfaction with once-weekly somatrogon vs once-daily rhGH | ||
| 520 | |a Methods: English-speaking investigators from somatrogon's global phase III study (NCT02968004) with prior experience using once-daily rhGH were included. Participants answered an online survey containing 14 closed- and open-ended items | ||
| 520 | |a Results: Twenty-four pediatric endocrinologists (41.7% men; 79.2% practiced at public/private hospitals) from 12 countries with 25.8 ± 12.0 years' experience treating pGHD completed the survey. In terms of the time and effort required to explain device instructions, injection regimen, procedure for missed injection, and address patients'/caregivers' concerns, a similar proportion of physicians chose once-weekly somatrogon and once-daily rhGH; 62.5% physicians indicated that once-daily rhGH required greater effort to monitor adherence. Overall, 75% preferred once-weekly somatrogon over once-daily rhGH, 79.2% considered once-weekly somatrogon to be more convenient and less burdensome, and 83.3% were likely to prescribe somatrogon in the future. Overall, 50% felt that once-weekly somatrogon was more beneficial to patients, while 50% chose "No difference". Most physicians (62.5%) felt both regimens were equally likely to support positive long-term growth outcomes and reduce healthcare utilization. More physicians were "very satisfied" with once-weekly somatrogon (62.5%) than with once-daily rhGH (16.7%). Reduced injection frequency, patient and caregiver burden, increased convenience, and improved adherence were reasons for these choices | ||
| 520 | |a Conclusion: Physicians had a positive experience with, and perception of, treating pGHD with once-weekly somatrogon | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a growth hormone deficiency | |
| 650 | 4 | |a long-acting growth hormone | |
| 650 | 4 | |a once-weekly injection regimen | |
| 650 | 4 | |a pediatric endocrinology | |
| 650 | 4 | |a somatrogon | |
| 650 | 4 | |a somatropin | |
| 650 | 4 | |a survey | |
| 650 | 4 | |a treatment experience | |
| 650 | 7 | |a Human Growth Hormone |2 NLM | |
| 650 | 7 | |a 12629-01-5 |2 NLM | |
| 650 | 7 | |a somatrogon |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 700 | 1 | |a Lamoureux, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Turner-Bowker, Diane M |e verfasserin |4 aut | |
| 700 | 1 | |a Loftus, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Maghnie, Mohamad |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Bradley S |e verfasserin |4 aut | |
| 700 | 1 | |a Polak, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Yaworsky, Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 14(2023) vom: 01., Seite 1254424 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:01 |g pages:1254424 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2023.1254424 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 01 |h 1254424 | ||